Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy

Anticancer Research

Volumn 20, Issue 6 D, 2000, Pages 5253-5255

  Hammerer, P ^a   Graefen, M ^a   Henke, R P ^a   Haese, A ^a   Palisaar, J ^a   Huland, E ^a   Huland, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Progression; Prostate specific antigen; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER STAGING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; MALE; MEASUREMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; RELAPSE; SCORING SYSTEM;

HUMANS; MALE; POSTOPERATIVE PERIOD; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROTEIN ISOFORMS; RECURRENCE;

EID: 0034451599     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Measurement of prostate specific antigen in serum as a screening test for prostate cancer
2. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate
3. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
4. Prostate-specific antigen in human serum occurs predominantly in complex with alpha-1 antichymotrypsin
5. A complex between prostate-specific antigen and alpha 1 antitrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
6. Comparision of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology
7. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: The best case scenario
8. Free-to-total prostate-specific antigen ratio as a single test for detection of significant stage Tlc prostate cancer
9. Serum percent free prostate-specific antigen in metastatic prostate cancer
10. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years
11. Serum PSA after anatomic radical prostatectomy. The Johns Hopskins experience after 10 years
12. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy
13. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
14. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
15. An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery
16. Morphologische Grundlagen zur radikalen Prostatektomie
17. Prostatic volume and ratio of free to total prostate-specific antigen in patients with prostatic cancer or benign prostatic hyperplasia
18. Value of ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer
19. Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer
20. Serum free/total prostatic specific antigen in prostate cancer patients treated with LH-RH agonists